Table 1

Meta-analysis of effect of LPV/r and Arbidol on COVID-19

HR/RR/WMD, 95% CIP value
Overall mortality
LPV/r/control*RR=0.68; 95% CI 0.39 to 1.19p=0.179
Case severity rate
LPV/r/control*RR=2.00; 95% CI 0.48 to 8.41p=0.344
Arbidol/control*RR=0.73; 95% CI 0.13 to 3.96p=0.714
LPV/r/Arbidol*RR=2.75; 95% CI 0.79 to 9.49p=0.110
The negative conversion time
LPV/r/controlWMD=-1,85; 95% CI −5.56 to 1.86p=0.373
Arbidol/controlWMD=0.08; 95% CI −1.65 to 1.81p=0.690
LPV/r/ArbidolWMD=0.75; 95% CI −0.97 to 2.48p=0.288
The negative conversion rate
LPV/r/controlRR=0.90; 95% CI 0.76 to 1.07p=0.225
Arbidol/controlRR=1.09; 95% CI 0.92 to 1.29p=0.340
LPV/r/ArbidolRR=0.76; 95% CI 0.57 to 1.01p=0.063
The length of hospital days
LPV/r/control*HR=1.12; 95% CI 0.8 to 1.56 
Arbidol/control*HR=0.50; 95% CI 0.75 to 1.28 
Adverse effects
LPV/r/controlRR=2.61; 95% CI 0.18 to 38.17p=0.483
Arbidol/control*RR=5.50; 95% CI 0.32 to 94.06p=0.239

  • *Means data from the published article.

  • LPV/r, lopinavir/ ritonavir ; RR, risk ratio ; WMD, weighted mean difference.